Erratum: Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting (Tumori (2013) 99, 6 (637-649) DOI: 10.1700/1390.15450);Prostate cancer as a paradigm of multidisciplinary approach? highlights from the italian young radiation oncologist meeting

Tumori

Volumn 99, Issue 6, 2013, Pages 637-649

  De Bari, Berardino ^a   Fiorentino, Alba ^b,n   Greto, Daniela ^c   Ciammella, Patrizia ^d   Arcangeli, Stefano ^e   Avuzzi, Barbara ^f   D'Angelillo, Rolando Maria ^g   Desideri, Isacco ^c   Kirienko, Margarita ^h   Marchiori, Debora ⁱ   Massari, Francesco ^j   Fundoni, Carla ^k   Franco, Pierfrancesco ^l   Filippi, Andrea R ^m   Alongi, Filippo ⁿ  

^a UNIVERSITY OF BRESCIA   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e Radiotherapy Unit   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^h UNIVERSITY OF MILANO BICOCCA   (Italy)

ⁱ Gynepro Private Clinic   (Italy)

^j UNIVERSITY OF VERONA   (Italy)

^k UOC di Radiologia   (Italy)

^l Ospedale Regionale U Parini   (Italy)

^m UNIVERSITY OF TURIN   (Italy)

ⁿ SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

more..

Author keywords

Diagnostic approach; Radical prostatectomy.; Therapeutic approach

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; ORTERONEL; PREDNISONE; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; VELIPARIB;

BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EDUCATION; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERDISCIPLINARY RESEARCH; ITALY; MEDICAL ONCOLOGIST; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN ATTITUDE; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION ONCOLOGIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT INDICATION; TREATMENT OUTCOME; UROLOGIST;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; INTERDISCIPLINARY COMMUNICATION; ITALY; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; ORCHIECTOMY; PATIENT CARE TEAM; PHYSICIAN'S PRACTICE PATTERNS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84894256447     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1578.17248     Document Type: Erratum

References (145)

1. Fox JJ, Schöder H, Larson SM: Molecular imaging of prostate cancer. Curr Opin Urol, 22: 320-327, 2012.
2. Jung AJ, Westphalen AC: Imaging prostate cancer. Radiol Clin North Am, 50: 1043-1059, 2012.
3. Munoz F, Fiandra C, Franco P, Guarneri A, Ciammella P, De Stefanis P, Rondi N, Moretto F, Badellino S, Iftode C, Ragona R, Ricardi U: Tracking target position variability using intraprostatic fiducial markers and electronic portal imaging in prostate cancer radiotherapy. Radiol Med, 117: 1057-1070, 2012.
4. Udrescu C, De Bari B, Rouvière O, Ruffion A, Michel-Amadry G, Jalade P, Devonec M, Colombel M, Chapet O: Does hormone therapy modify the position of the gold markers in the prostate during irradiation? A daily evaluation with kV-images. Cancer Radiother, 17: 215-220, 2013.
5. Arcangeli S, Scorsetti M, Alongi F: Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol, 84: 101-108, 2012.
6. Close A, Robertson C, Rushton S, Shirley M, Vale L, Ramsay C, Pickard R: Comparative cost-effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of men with localised prostate cancer: a health technology assessment from the perspective of the UK National Health Service. Eur Urol, 64: 361-369, 2013.
7. Alva A, Hussain M: The changing natural history of metastatic prostate cancer. Cancer J, 19: 19-24, 2013.
8. Alongi F, De Bari B, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR; on behalf of AIRO Young and AIRO Prostate cancer Working Group: The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiol Med, 118: 660-678, 2013.
9. De Bari B, Alongi F, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR; on behalf of AIRO Young and AIRO Prostate cancer Working Group: The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II) - A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiol Med, 118: 1220-1229, 2013.
10. Filippi AR, Alongi F, Ciammella P, De Bari B, Franco P, Livi L: A strategy for young members within national radiation oncology societies: The Italian experience (AIRO Giovani group). Rep Pract Oncol Radiother, 17: 259-261, 2012.
11. De Bari B, Chiesa S, Filippi AR, Gambacorta MA, D'Emilio V, Murino P, Livi L; AIRO (Italian Association of Radiation Oncology) and the AIRO Palliative Care Group: The INTER-ROMA project- a survey among Italian radiation oncologists on their approach to the treatment of bone metastases. Tumori, 97: 177-184, 2011.
12. Pegurri L, Buglione M, Girelli G, Guarneri A, Meattini I, Ricardi U, Mangoni M, Gabriele P, Bellavita R, Krengli M, Bonetta A, Cagna E, Bunkheila F, Borghesi S, Signor M, DiMarco A, Bertoni F, Stefanacci M, Gatta R, De Bari B, Magrini S: Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society (AIRO). Tumori 2014, in press.
13. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 49: 1374-1403, 2013.
14. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE; SPCG-4 Investigators: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med, 364: 1708-1717, 2011.
15. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med, 367: 203-213, 2012.
16. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F: Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol, 55: 1321-1330, 2009.
17. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ: Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol, 63: 597-603, 2013.
18. Klotz L: active surveillance for prostate cancer: a Review. Curr Urol Rep, 11: 165-171, 2010.
19. Bellardita L, Rancati T, Alvisi MF, Villani D, Magnani T, Marenghi C, Nicolai N, Procopio G, Villa S, Salvioni R, Valdagni R: Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol, 64: 30-36, 2013.
20. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA: Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol, 30: 3071-3076, 2012.
21. Magnani T, Valdagni R, Salvioni R, Villa S, Bellardita L, Donegani S, Nicolai N, Procopio G, Bedini N, Rancati T, Zaffaroni N: The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int, 110: 998-1003, 2012.
22. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA, 300: 173-181, 2008. (Pubitemid 351969301)
23. Lu-Yao GL, Albertsen PC, Li H, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL: Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer? Eur Urol, 62: 966-972, 2012.
24. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group: Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int, 105: 1074-1081, 2010.
25. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ; European Society of Urogenital Radiology: ESUR prostate MR guidelines 2012. Eur Radiol, 22: 746-757, 2012.
26. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S: Prostate cancer screening: the clinical value of diffusion weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging, 25: 146-152, 2007. (Pubitemid 46095209)
27. Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D, Scardino PT, Hricak H: Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology, 239: 784-792, 2006. (Pubitemid 43830614)
28. Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, Kitagaki H, Igawa M: Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol, 49: 1207-1213, 2008.
29. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K: Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging, 31: 625-631, 2010.
30. Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, Hulsbergen-Van de Kaa CA, Witjes JA, Krabbe PF, Heerschap A, Barentsz JO: Prostate cancer localization with dynamic contrast enhanced MR imaging and proton MR spectroscopic imaging. Radiology, 241: 449-458, 2006. (Pubitemid 44632891)
31. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D: Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol, 19: 761-769, 2009.
32. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Ménard C, Warde P, Trachtenberg J, Lockwood G, Milosevic M: Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys, 70: 425-430, 2008.
33. van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP, Parker CC: A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol, 56: 981-987, 2009.
34. Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H: Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging, 33: 167-172, 2011.
35. Hambrock T, Huisman HJ, van Oort IM, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, Scheenen T, Barentsz JO: Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology, 259: 453-461, 2011.
36. Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, Kurhanewicz J, Manferrari F, Brunocilla E, Tonon C, Monetti N, Castellucci P, Fanti S, Coe M, Grigioni WF, Martorana G, Canini R, Barbiroli B: Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology, 244: 797-806, 2007. (Pubitemid 47292091)
37. Kurhanewicz J, Vigneron D, Carroll P, Coakley F: Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol, 18: 71-77, 2008. (Pubitemid 350307535)
38. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol, 77: 340-345, 2011.
39. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Di Silverio F, Gentile V: Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol, 54: 589-600, 2008.
40. De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM: Role of MRI in follow-up after focal therapy for prostate carcinoma. Am J Roentgenol, 194: 1427-1433, 2010.
41. Fox JJ, Schoder H, Larson SM: Molecular imaging of prostate cancer. Curr Opin Urol, 22: 320-327, 2012
42. Krause BJ, Souvatzoglou M, Treiber U: Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol, 31: 427-435, 2013.
43. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM: The Role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol, 64: 106-117, 2013.
44. Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, Eiber M, Herrmann K, Kuebler H, Wester HJ, Hoefler H, Gschwend J, Schwaiger M, Treiber U, Krause BJ: The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res, 17: 3751-3759, 2011.
45. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W: 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology, 254: 925-933, 2010.
46. Soyka JD, Muster MA, Schmid DT, Seifert B, Schick U, Miralbell R, Jorcano S, Zaugg K, Seifert HH, Veit-Haibach P, Strobel K, Schaefer NG, Husarik DB, Hany TF: Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging, 39: 936-943, 2012.
47. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S: Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med, 50: 1394-1400, 2009.
48. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, Schuster T, Geinitz H, Treiber U, Schwaiger M: The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging, 35: 18-23, 2008. (Pubitemid 350234152)
49. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN: The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol, 59: 51-60, 2011.
50. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S: Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging, 38: 55-63, 2011.
51. Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C: Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med, 37: 325-331, 2012.
52. Dost RJ, Glaudemans AW, Breeuwsma AJ, de Jong IJ: Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer. Eur J Nucl Med Mol Imaging, 40 Suppl 1: 41-47, 2013.
53. Giovacchini G: Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline? Eur J Nucl Med Mol Imaging, 38: 1964-1966, 2011.
54. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol, 59: 61-71, 2011.
55. Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT): Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol, 63: 693-701, 2013.
56. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol, 59: 572-583, 2011.
57. Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W: Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int, 109 Suppl 2: 8-13, 2012.
58. Hatiboglu G, Teber D, Hohenfellner M: Robot-assisted prostatectomy: the new standard of care. Langenbecks Arch Surg, 397: 343-352, 2012.
59. Porpiglia F, Morra I, Lucci Chiarissi M, Manfredi M, Mele F, Grande S, Ragni F, Poggio M, Fiori C: Randomised controlled trial comparing laparoscopic and robot-assisted radical prostatectomy. Eur Urol, 63: 606-614, 2013.
60. Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM: Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. BJU Int, 109: 898-905, 2012.
61. Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P: Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol, 62: 1-15, 2012.
62. Moore BM, Savdie R, PeBenito RA, Haynes AM, Matthews J, Delprado W, Rasiah KK, Stricker PD: The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy. BJU Int, 109: 533-538, 2012.
63. Spinelli MG, Cozzi G, Grasso A, Talso M, Varisco D, Abed El Rahman D, Acquati P, Albo G, Rocco B, Maggioni A, Rocco F: RALP and Rocco stitch: original technique. Urologia, 78 Suppl 18: 35-38, 2011.
64. Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ; American Brachytherapy Society: American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy, 11: 6-19, 2012.
65. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L; ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group: ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol, 57: 315-321, 2000.
66. Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, Venselaar J, Hoskin P; GEC ESTRO PROBATE Group: Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol, 83: 3-10, 2007. (Pubitemid 46527942)
67. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H: Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol, 176: 1415-1419, 2006. (Pubitemid 44307191)
68. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM: Multi-institutional analysis of long-term outcome for stages T1(T2) prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys, 67: 327-333, 2007. (Pubitemid 46108308)
69. Morris WJ, Keyes M, Palma D, Spadinger I, McKenzie MR, Agranovich A, Pickles T, Liu M, Kwan W, Wu J, Berthelet E, Pai H: Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology, 73: 860-867, 2009.
70. Hinnen KA, Jan JB, van Roermund JG, Moerland MA, Jürgenliemk-Schulz IM, Frank SJ, van Vulpen M: Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys, 76: 1433-1438, 2010.
71. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys, 58: 25-33, 2004. (Pubitemid 38010333)
72. Vassil AD, Murphy ES, Chandana A, Angermeier KW, Altman A, Chehade N, Ulchaker J, Klein EA, Ciezki JP: Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology, 76: 1251-1257, 2010.
73. Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK: Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer, 115: 5596-5606, 2009.
74. Zelefsky MJ, Yamada Y, Pei X, Hunt M, Cohen G, Zhang Z, Zaider M: Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology, 77: 986-993, 2011.
75. Hunter GK, Reddy CA, Klein EA, Kupelian P, Angermeier K, Ulchaker J, Chehade N, Altman A, Ciezki JP: Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer, doi: 10.1155/2012/853487, 2012.
76. Klein EA, Ciezki J, Kupelian PA, Mahadevan A: Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol, 27: 67-71, 2009.
77. Potters L, Klein MA, Kattan MV, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA: Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol, 71: 29-33, 2004. (Pubitemid 38452899)
78. Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A: Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys, 82: 204-212, 2012.
79. Chiumento C, Montagna A, Clemente S, Cozzolino M, Fusco V: A retrospective analysis after low-dose rate prostate brachytherapy with permanent 125I seed implant: clinical and dosimetric results in 70 patients. Tumori, 97: 335-340, 2011.
80. Chiumento C, Fiorentino A, Cozzolino M, Caivano R, Clemente S, Pedicini P, Fusco V: Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy. Chin J Cancer Res, 25: 274-280, 2013.
81. Guarneri A, Botticella A, Filippi AR, Munoz F, Beltramo G, Casetta G, Giglioli FR, Tizzani A, Ragona R, Ricardi U: 125I brachytherapy for localized prostate cancer: a single institution experience. Tumori, 99: 83-87, 2013.
82. Maggio A, Panaia R, Garibaldi E, Bresciani S, Malinverni G, Stasi M, Gabriele P: Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy. Tumori, 98: 722-727, 2012.
83. Tramacere F, Gianicolo EA, Pignatelli A, Portaluri M: High-dose 3D-CRT in the radical and postoperative setting for prostate cancer. Analysis of survival and late rectal and urinary toxicity. Tumori, 98: 337-343, 2012.
84. Fowler J, Chappel R, Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys, 50: 1021-1031, 2001. (Pubitemid 32594841)
85. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP: Direct evidence that prostate tumors shows high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys, 52: 6-13, 2002. (Pubitemid 34041562)
86. Williams SG, Taylor JM, Liu N, Tra Y, Duchesne GM, Kestin LL, Martinez A, Pratt GR, Sandler H: Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys, 68: 24-33, 2007. (Pubitemid 46589844)
87. Pedicini P, Strigari L, Benassi M: Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys, 85: e231-237, 2013.
88. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W: A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol, 23: 6132-6138, 2005.
89. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J: Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys, 81: 1271-1278, 2011.
90. Kuban DA, Nogueras-Gonzalez NG, Hamblin L, Lee AK, Choi S, Frank SJ, Nguyen QN, Hoffman KE, McGuire SE, Munsell MF: Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys, 78(suppl): S58, 2010.
91. Pollack AW, Walker G, Buyyounouski M, Horwitz E, Price R, Feigenberg S, Konski A, Stoyanova R, Ma C: Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys, 81(suppl): S1, 2011.
92. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnarò P, Pinzi V, Arcangeli G: Updated results and pattern of failures in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys, 84: 1172-1178, 2012.
93. Dearnaley D, Syndicus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E: Conventional versus hypofractionated high dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from CHHiP randomized controlled trial. Lancet Oncol, 13: 43-54, 2012.
94. Kang JK, Cho CK, Choi CW, Yoo S, Kim MS, Yang K, Yoo H, Kim JH, Seo YS, Lee DH, Jo M: Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori, 97: 43-48, 2011.
95. Zerini D, Jereczek-Fossa BA, Vavassori A, Bossi-Zanetti I, Mauro R, Ivaldi GB, Trovò M, Cambria R, Garibaldi C, Cattani F, Orecchia R: 3D-conformal hypofractionated radiotherapy for prostate cancer with daily transabdominal ultrasonography prostate localization: toxicity and outcome of a pilot study. Tumori, 96: 941-946, 2010.
96. Zumsteg ZS, Zelefsky MJ: Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol, 13: e259-269, 2012.
97. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med, 365: 107-118, 2011.
98. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW: Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA, 299: 289-295, 2008. (Pubitemid 351159365)
99. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C: Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol, 12: 451-459, 2011.
100. Roach M III, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV: Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol, 26: 585-591, 2008. (Pubitemid 351264352)
101. Laverdière J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F: The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol, 171: 1137-1140, 2004. (Pubitemid 38327543)
102. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA: Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer, 48: 1664-1671, 2012.
103. Dubray BM, Beckendorf V, Guerif S, Le Prise E, Reynaud-Bougnoux A, Hannoun Levi JM, Nguyen TD, Hennequin C, Cretin J, Fayolle-Campana M, Lagrange J, Bachaud J, Azria D, Grangirard A, Pommier P, Simon J, Harter V, Habibian M: Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediate analysis of GETUG 14 randomized trial (EU-20503/NCT00104741). Proc Am Soc Clin Oncol, 29(suppl): 4521(abstr), 2011.
104. Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, Yamada Y, Fidaleo A, Sperling D, Happersett L, Zhang Z: Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol, 60: 1133-1139, 2011.
105. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A: Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys, 79: 1310-1317, 2011.
106. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU: Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol, 26: 2497-2504, 2008.
107. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L: External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol, 11: 1066-1073, 2010.
108. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med, 360: 2516-2527, 2009.
109. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys, 61: 1285-1290, 2005. (Pubitemid 40470408)
110. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W; NCIC CTG PR.3/MRC UK PR07 investigators: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet, 378: 2104-2111, 2011.
111. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA: Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol, 20: 3376-3385, 2002.
112. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans
113. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol, 181: 956-962, 2009.
114. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol, 27: 2924-2930, 2009.
115. Alongi F, Cozzarini C, Di Muzio N, Scorsetti M: Postoperative radiotherapy in prostate cancer: acquired certainties and still open issues. A review of recent literature. Tumori, 97: 1-8, 2011.
116. King CR: The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys, 84: 104-111, 2012.
117. Ohri N, Dicker AP, Trabulsi EJ, Showalter TN: Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer, 48: 837-844, 2012.
118. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R: Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastastic prostate cancer. Int J Radiat Oncol Biol Phys, 82: 889-897, 2012.
119. Ricchetti F, Barra S, Agostinelli S, Vagge S, Marcenaro M, Corvò R: Feasibility of helical tomotherapy for radical dose retreatment in pelvic area: a report of 4 cases. Tumori, 97: 492-497, 2011.
120. 125 Iodine reimplantation for locally progressive prostatic carcinoma. J Urol, 144: 704-706, 1990.
121. Loening SA, Turner JW: Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate, 23: 283-290, 1993. (Pubitemid 24020886)
122. Nguyen PL, Chen MH, D'Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW: Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer, 110: 1485-1492, 2007. (Pubitemid 47463062)
123. Koutrouvelis P, Hendricks F, Lailas N, Gil-Montero G, Sehn J, Khawand N, Bondy H, Katz S: Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three-dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat, 2: 339-344, 2003. (Pubitemid 37022351)
124. Beyer DC: Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology, 54: 880-883, 1999.
125. Wong WW, Buskirk SJ, Schild SE, Prussak KA, Davis BJ: Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol, 176: 2020-2024, 2006. (Pubitemid 44633176)
126. Moman MR, van der Poel HG, Battermann JJ, Moerland MA, van Vulpen M: Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy, 9: 119-125, 2010.
127. Burri RJ, Stone NN, Unger P, Stock RG: Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 77: 1338-1344, 2010.
128. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, Larson TR, Wilkes MM, Navickis RJ: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology, 53: 2-10, 1999. (Pubitemid 29016606)
129. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd: Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys, 85: 370-377, 2013.
130. Jo Y, Fujii T, Hara R, Yokoyama T, Miyaji Y, Yoden E, Hiratsuka J, Nagai A: Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary results. BJU Int, 109: 835-839, 2012.
131. Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M 3rd, Hsu IC: Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California - San Francisco experience. Int J Radiat Oncol Biol Phys, 67: 1106-1112, 2007.
132. Engels B, Soete G, Tournel K, Bral S, De Coninck P, Verellen D, Storme G: Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity. Technol Cancer Res Treat, 8: 353-359, 2009.
133. Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C, Cambria R, Brait L, Possanzini M, Bianchi LC, Vavassori A, Zerini D, Orsi F, de Cobelli O, Orecchia R: Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol, 93: 14-17, 2009.
134. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, Gulisano M, Aterini S: Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori, 97: 49-55, 2011.
135. Rigatti P, Suardi N, Bridanti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F: Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol, 60: 935-943, 2011.
136. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351: 1513-1520, 2004. (Pubitemid 39315318)
137. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 351: 1502-1512, 2004. (Pubitemid 39315317)
138. Massari F, Maines F, Modena A, Brunelli M, Bria E, Artibani W, Martignoni G, Tortora G: Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. Anticancer Agents Med Chem, 13: 872-886, 2013.
139. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364: 1995-2005, 2011.
140. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, 368: 138-148, 2013.
141. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, De Wit R, Mulders P Hirmand M, Selby B, De Bono JS, for the AFFIRM Investigators: Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol, 30 (5 Suppl): LBA1, 2012.
142. George D, Moul JW: Emerging treatment options for patients with castration-resistant prostate cancer. Prostate, 72: 338-349, 2012.
143. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol, 24: 3089-3094, 2006. (Pubitemid 46638945)
144. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with si-puleucel- T in advanced prostate cancer. Cancer, 115: 3670-3679, 2009.
145. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363: 411-422, 2010.